Crinetics News

Crinetics Pharmaceuticals Grants Stock Options to New Employees Under 2021 Inducement Plan

Quiver QuantitativeDec 10 20:50 ET

Express News | Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersDec 10 20:44 ET

Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireDec 10 20:44 ET

JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $87

Moomoo NewsDec 9 10:31 ET · Ratings

Crinetics Announces FDA Acceptance of NDA for Paltusotine

TipRanksDec 9 09:38 ET

Express News | Crinetics Pharmaceuticals Inc - FDA Targets Pdufa Date Sept 25, 2025 for Nda Review Completion

ReutersDec 9 08:04 ET

Express News | Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients With Acromegaly

ReutersDec 9 08:00 ET

Cushing Syndrome Pipeline Insight 2024, Featuring Key Players Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals and Key Products Relacorilant, SPI 62 and CRN-04894

Yahoo FinanceDec 6 04:14 ET

Crinetics Price Target Raised to $87 From $80 at JMP Securities

TipRanksDec 5 06:40 ET

Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Halozyme (HALO) and Crinetics Pharmaceuticals (CRNX)

TipRanksNov 27 00:42 ET · Ratings

LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $82

Moomoo NewsNov 22 15:31 ET · Ratings

Promising Outlook for Crinetics Pharmaceuticals' Paltusotine in Phase 3 Trial Drives Buy Rating

TipRanksNov 22 14:35 ET · Ratings

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

GlobeNewswireNov 15 09:00 ET

Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 Loss per Share (Vs US$1.01 Loss in 3Q 2023)

Yahoo FinanceNov 14 07:38 ET

Citi Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $74

Moomoo NewsNov 14 07:31 ET · Ratings

Crinetics Pharmaceuticals: Promising Future With Innovative Drug Developments and Strong Financial Position

TipRanksNov 14 02:38 ET

Crinetics Pharmaceuticals Analyst Ratings

BenzingaNov 13 13:45 ET · Ratings

JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $71

Moomoo NewsNov 13 10:31 ET · Ratings

Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97

Moomoo NewsNov 13 08:31 ET · Ratings

Piper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)

TipRanksNov 13 08:19 ET · Ratings